GetTopicDetailResponse(id=03d2622088, topicName=DPP4i, introduction=DPP4i, content=null, image=null, comments=2, allHits=1788, url=https://h5.medsci.cn/topic?id=6220, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=40233, tagList=[TagDto(tagId=40233, tagName=DPP4i)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2118789, encodeId=3d6f2118e8947, content=<a href='/topic/show?id=f3ad840081f' target=_blank style='color:#2F92EE;'>#胰高血糖素樣肽-1#</a> （<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>）為基礎(chǔ)的藥物，包括<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受體激動劑#</a>（GLP-1RA）和<a href='/topic/show?id=788a24043af' target=_blank style='color:#2F92EE;'>#二肽基肽酶-4抑制劑#</a> （<a href='/topic/show?id=03d2622088' target=_blank style='color:#2F92EE;'>#DPP4i#</a>），是用于治療<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a>的<a href='/topic/show?id=98e610556057' target=_blank style='color:#2F92EE;'>#腸促胰素類藥物#</a>。除了腸促胰素效應(yīng)外，GLP-1為基礎(chǔ)的藥物還具有<a href='/topic/show?id=98c0553894c' target=_blank style='color:#2F92EE;'>#抗炎#</a>作用。然而，既往一項(xiàng)研究報(bào)告使用DPP4i會增加<a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎癥性腸病#</a>（IBD）風(fēng)險(xiǎn)。, objectTitle=ECCO 2023 | GLP-1為基礎(chǔ)的藥物與炎癥性腸病風(fēng)險(xiǎn)：來自國家隊(duì)列研究的真實(shí)世界證據(jù), objectType=article, longId=762356, objectId=7d8be62356b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/361cfc26c42642a891ede2db100a3ffa.jpg, objectUrl=/article/show_article.do?id=7d8be62356b3, replyNumber=0, likeNumber=223, createdTime=2023-03-11, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7d8be62356b3, moduleTitle=ECCO 2023 | GLP-1為基礎(chǔ)的藥物與炎癥性腸病風(fēng)險(xiǎn)：來自國家隊(duì)列研究的真實(shí)世界證據(jù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7d8be62356b3)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2090266, encodeId=36642090266fe, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲雙胍#</a>通常是T2D的一線治療，并在許多臨床試驗(yàn)中形成基礎(chǔ)治療，這些臨床試驗(yàn)評估了新的GLD。替代GLD包括鈉-葡萄糖共轉(zhuǎn)運(yùn)體2抑制劑(<a href='/topic/show?id=5c331622ee1' target=_blank style='color:#2F92EE;'>#SGLT2i#</a>)、胰高血糖素樣肽-1受體激動劑(GLP-1RA)、二肽基肽酶4抑制劑(<a href='/topic/show?id=03d2622088' target=_blank style='color:#2F92EE;'>#DPP4i#</a>)、<a href='/topic/show?id=2573e388589' target=_blank style='color:#2F92EE;'>#磺脲類藥物#</a>。<a href='/topic/show?id=f8dd10420ed3' target=_blank style='color:#2F92EE;'>#格列齊特#</a>、<a href='/topic/show?id=abae62296da' target=_blank style='color:#2F92EE;'>#格列美脲#</a>、<a href='/topic/show?id=d7dd62295e4' target=_blank style='color:#2F92EE;'>#格列本脲#</a>這些老藥也并不差。<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>, objectTitle=DOM：使用亞洲聯(lián)合糖尿病評估(JADE)登記系統(tǒng)研究磺脲類藥物在亞洲二型糖尿病患者中的實(shí)際應(yīng)用, objectType=article, longId=740818, objectId=41cee4081830, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/2zKK-712x400.jpg, objectUrl=/article/show_article.do?id=41cee4081830, replyNumber=0, likeNumber=224, createdTime=2022-09-25, rootId=0, userName=小小醫(yī)者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41cee4081830, moduleTitle=DOM：使用亞洲聯(lián)合糖尿病評估(JADE)登記系統(tǒng)研究磺脲類藥物在亞洲二型糖尿病患者中的實(shí)際應(yīng)用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=41cee4081830)], followStatus=false, userIsMember=false, type=1, lengthMark=1)]
梅斯話題小助手
2020-05-29
